COVID-19 Vaccine Passes First Human Trial, Declared Safe For Use
Phase1 human trial of a COVID-19 vaccine called the Ad5-nCoV shows that it is safe, well-tolerated and able to generate an immune response against the SARS-CoV-2 in participants. The trial demonstrates that a single dose of the new vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation.